PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1394158
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1394158
The global High Potency Active Pharmaceutical Ingredients (HPAPI) market, with a valuation of approximately US$ 25 billion in 2024, is poised for significant growth during forecast period 2024 to 2031. The prevalence of cancer cases worldwide has driven the increased use of HPAPIs, propelling market expansion.
The patent expiration of successful drugs in the pharmaceutical industry offers a lucrative opportunity for businesses to diversify their product portfolios and enter attractive market segments. Europe has seen several biosimilars approvals, while the United States FDA has approved a limited number so far. Continuous research and development efforts aimed at replicating branded biological medications are likely to lead to the introduction of cost-effective treatment options.
Several key medications, including Remicade (Infliximab), Herceptin (Trastuzumab), Avastin (Bevacizumab), Erbitux (Cetuximab), Synagis (Palivizumab), Humira (Adalimumab), and Rituxan (Rituximab), are expected to lose their patent protection, presenting significant opportunities for biosimilars in the market.
Stringent regulatory standards for pharmaceutical ingredient production in various countries have driven up in-house API manufacturing costs. Consequently, pharmaceutical companies are increasingly turning to outsourcing to optimize their operations. Asia Pacific, with its cost-effective production capabilities, has become a preferred destination for outsourcing API manufacturing.
Several manufacturers have established a strong presence in countries like China and India, leading to a surge in contract development and manufacturing firms (CDMOs). For instance, AGC Biologics, a global biopharmaceutical CDMO, collaborated with Ono Pharmaceutical Co., Ltd. in 2020 for the development of innovative biopharmaceuticals. This expertise and capacity to manufacture APIs at scale are expected to boost the market in the forecast period.
North America: The North American market is expected to be the most lucrative, driven by the increasing prevalence of chronic diseases and government initiatives to develop new medications. The rising adoption of biological pharmaceuticals among patients further contributes to the demand for biological APIs.
Asia Pacific: The market in Asia Pacific is set to surge, driven by the growing presence of contract manufacturing organizations and pharmaceutical companies in countries like China and India.
Key Companies Profiled in the HPAPI Market:
Market Segments Covered in High Potency Active Pharmaceutical Ingredients Market Analysis